Factors associated with the number of drugs in darunavir/cobicistat regimens
Open Access
- 5 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 75 (1) , 208-214
Abstract
Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. To assess factors associated with the number of drugs in darunavir/cobicistat regimens. A nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat in Spain from July 2015 to May 2017. Baseline characteristics, efficacy and safety at 48 weeks were compared according to the number of drugs used. There were 761 patients (75% men, 98% were antiretroviral-experienced, 32% had prior AIDS, 84% had HIV RNA 3) who initiated darunavir/cobicistat as mono (n=308, 40%), dual (n=173, 23%), triple (n=253, 33%) or four-drug (n=27, 4%) therapy. Relative to monotherapy, triple therapy was more common in men aged 3 and with detectable viral load at initiation of darunavir/cobicistat; dual therapy was more common with previous intravenous drug use, detectable viral load at initiation of darunavir/cobicistat and no prior darunavir plus ritonavir; and four-drug therapy was more common with prior AIDS and detectable viral load at initiation of darunavir/cobicistat. Monotherapy and dual therapy showed a trend to better virological responses than triple therapy. CD4 responses and adverse effects did not differ among regimens. Darunavir/cobicistat use in Spain has been tailored according to clinical characteristics of HIV-infected patients. Monotherapy and dual therapy have been common and preferentially addressed to older patients with a better HIV status, suggesting that health issues other than HIV infection may have been strong determinants of its prescription.Keywords
Funding Information
- CODAR (9316)
- Sociedad Española de Enfermedades Infecciosas y Microbiología-Grupo de Estudio del SIDA
- SEIMC
- GESIDA
- Janssen Cilag S.A.
- Red de Investigación en SIDA (RIS-EST29, RD12/0017/0001, RD12/0017/0005, RD17/0017/0022, RD17/0017/0029)
This publication has 20 references indexed in Scilit:
- Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2017)Enfermedades Infecciosas y Microbiología Clínica, 2018
- Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialClinical Infectious Diseases, 2017
- Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV‐1‐infected subjects with dyslipidaemiaHIV Medicine, 2017
- Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important DifferencesAnnals of Pharmacotherapy, 2017
- Impact of polypharmacy on antiretroviral prescription in people living with HIVJournal of Antimicrobial Chemotherapy, 2016
- Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016)Enfermedades Infecciosas y Microbiología Clínica, 2016
- Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trialHIV Medicine, 2016
- The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mlAIDS, 2010
- Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsThe Lancet, 2007
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998